EnVVeno Medical Corporation (NVNO)
NASDAQ (CM) NASDAQ (CM) Primary Summary
NVNO's Shares Decline on Unfavorable FDA Review Outcome for VenoValve
enVVeno Medical shares plunge after the FDA rejects its VenoValve PMA, citing insufficient trial data and safety concerns tied to the surgical procedure.
enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website
Interviews with participating patients from the VenoValve® U.S. Pivotal Trial Webcast replay from with the presenting Primary Investigators Presentation with data from the VenoValve U.S. Pivotal Trial Access the Recap Website Here! IRVINE, CA / ACCESSWIRE / November 27, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the launch of a recap website which highlights the Company's participation at the recently held 51st Annual Vascular and Endovascular, Techniques and Horizons (VEITH) Symposium.
NVNO Completes Application for VenoValve's PMA, Shares Likely to Gain
The FDA's approval of VenoValve's PMA has the potential to significantly expand NVNO's portfolio of bioprosthetic solutions.
EnVVeno Medical Corporation (NVNO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has EnVVeno Medical Corporation ever had a stock split?
EnVVeno Medical Corporation Profile
| Health Care Technology Industry | Healthcare Sector | Robert A. Berman CEO | NASDAQ (CM) Exchange | 29415J106 CUSIP |
| US Country | 37 Employees | 30 Nov 2020 Last Dividend | 20 Jan 2026 Last Split | 31 May 2018 IPO Date |
Overview
enVVeno Medical Corporation is a clinical-stage medical device company dedicated to advancing the treatment of venous diseases through innovative bioprosthetic tissue-based solutions. Initially known as Hancock Jaffe Laboratories, Inc., the company underwent a name change to enVVeno Medical Corporation in October 2021, marking a new chapter in its mission to improve the standard of care for patients suffering from venous conditions. Founded in 1999 and headquartered in Irvine, California, enVVeno Medical Corporation leverages its expertise in medical device development to address the unmet needs of patients with Chronic Venous Insufficiency (CVI) and other venous disorders.
Products and Services
- VenoValve
A surgical implant designed for the treatment of Chronic Venous Insufficiency (CVI), the VenoValve represents enVVeno Medical Corporation's flagship product. Aimed at patients suffering from this debilitating condition, the VenoValve is surgically placed in the femoral vein. It functions as a one-way valve, restoring proper blood flow in the leg by preventing the backward flow of blood. This innovative approach offers hope for improving the quality of life for those affected by CVI, showcasing enVVeno Medical Corporation's commitment to addressing complex venous diseases with advanced medical technologies.
- enVVe
enVVe serves as a non-surgical, transcatheter-based venous valve replacement solution, signifying another key component of enVVeno Medical Corporation's product line aimed at treating CVI. This revolutionary product offers a less invasive alternative to traditional surgery, designed to replicate the function of healthy venous valves. By facilitating the restoration of normal blood flow through minimally invasive means, enVVe exemplifies the company's innovation in providing effective treatment options for patients seeking relief from the symptoms of Chronic Venous Insufficiency.
